Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

If you are facing a recurrence of classic Hodgkin lymphoma, or you have become resistant to your treatment, there is some ...

M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...

Understanding the investment thesis for Merck requires appreciating the importance of its blockbuster cancer drug, Keytruda, ...

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Natalie Willacy has so far poured $40,000 of her super into self-funding her own immunotherapy treatment with the ...